Extreme outlier analysis identifies occult mitogen- activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
Drug Resistance, Neoplasm
MAP Kinase Kinase 1
Neoplasms, Glandular and Epithelial
Alterations affecting the mitogen-activated protein kinase pathway are present in the majority of patients with LGS ovarian cancer. Next-generation sequencing analysis revealed deletions and fusions that are not detected by older sequencing approaches. These findings, coupled with the observation that a subset of patients with recurrent LGS ovarian cancer experienced dramatic and durable responses to MEK inhibitor therapy, support additional clinical studies of MEK inhibitors in this disease.